Inc » Trang Công Nghệ | Trangcongnghe.vn

Globe Newswire

urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 — Potential Record 600-Player Pool, World-Class Marquee Talent, and Expected Appointment of Chris Gayle as Global Brand Ambassador

Globenewswire -

urban-gro, Inc. Outlines Strategy Targeting Global T20 Cricket Market and Near-Term Execution Milestones

Globe Newswire

urban-gro, Inc. Outlines Strategy Targeting Global T20 Cricket Market and Near-Term Execution Milestones

Globenewswire -

Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.

Globe Newswire

Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.

Globenewswire -

urban-gro, Inc. Positions for Entry into Multi-Billion-Dollar T20 Cricket Market with LPL Season Six Player Auction on May 15, 2026 via IPG Platform

Globe Newswire

urban-gro, Inc. Positions for Entry into Multi-Billion-Dollar T20 Cricket Market with LPL Season Six Player Auction on May 15, 2026 via IPG Platform

Globenewswire -

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

Globe Newswire

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

Globenewswire -

IPG to Expand T20 Cricket Footprint Across Sri Lanka, Malaysia and Zimbabwe Following Merger with Flash Sports & Media, Inc., following Flash’s merger with NASDAQ-listed urban-gro, Inc.

Globe Newswire

IPG to Expand T20 Cricket Footprint Across Sri Lanka, Malaysia and Zimbabwe Following Merger with Flash Sports & Media, Inc., following Flash’s merger with NASDAQ-listed urban-gro, Inc.

Globenewswire -

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Globe Newswire

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Globenewswire -

XEM THÊM TIN MỚI